Seven-Year Visual and Anatomical Outcomes of Intravitreal Vascular Endothelial Growth Factor Inhibition for Neovascular Age-Related Macular Degeneration
Table 1
Mean VA development for the respective cohort from baseline to each year in total, separated in baseline VA and amount of intravitreal injections/year in Snellen.
Years
VA (n)
≥20/50 (n)
20/50–20/114 (n)
≤20/114 (n)
<3 IVI/year (n)
34 IVI/year (n)
>4 IVI/year (n)
0
20/63 + 1 (124)
20/40 + 1 (65)
20/80 + 2 (37)
20/160–1 (22)
20/63 (50)
20/63 + 2 (31)
20/63 + 2 (43)
1
20/50 + 1 (119)
20/40 + 1 (62)
20/63–1 (33)
20/100 (20)
20/63–1 (43)
20/50 (31)
20/40–2 (44)
2
20/50–2 (119)
20/40 (64)
20/80 (32)
20/100 (20)
20/63–2 (43)
20/50 (32)
20/50 + 1 (44)
3
20/63 + 1 (119)
20/40–2 (64)
20/100 + 2 (32)
20/100 (20)
20/63–1 (42)
20/63 + 1 (33)
20/63 + 2 (44)
4
20/63–1 (119)
20/50 + 1 (64)
20/100 (33)
20/100–1 (19)
20/80 + 1 (42)
20/63 + 2 (33)
20/63–1 (44)
5
20/63–1 (119)
20/50 (63)
20/100 + 1 (34)
20/100–1 (20)
20/80 (42)
20/63–1 (33)
20/63 + 1 (44)
6
20/80 + 1 (87)
20/63 + 1 (51)
20/100 + 2 (22)
20/125 (13)
20/100 + 2 (32)
20/80 + 2 (23)
20/63–1 (32)
7
20/100 + 2 (45)
20/80–2 (25)
20/100 (15)
20/80–1 (5)
20/125 + 1 (13)
20/100 (12)
20/63–2 (20)
Letters
−9
−18
−6
+14
−19
−11
−4
VA = visual acuity; n = number of eyes; IVI = intravitreal injection; change in letters ETDRS = Early treatment diabetic retinopathy study chart at 4 meters.
